PLX News 4.15 Protalix Biotherapeutics (PLX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Protalix Biotherapeutics (PLX) 4.15 $PLX

Protalix BioTherapeutics Up 5.1%, Shares Break Through Resistance (PLX)
Comtex SmarTrend(R) - Tue Mar 25, 12:45PM CDT
Protalix BioTherapeutics (AMEXLX) is one of today's best performing low-priced stocks, up 5.1% to $4.76 on 1.1x average daily volume. Protalix BioTherapeutics has traded 246,000 shares thus far today, vs. average volume of 232,000 shares per day. The stock has outperformed the Dow (5.1% to the Dow's 0.7%) and outperformed the S&P 500 (5.1% to the S&P's 0.5%) during today's trading.

Uptrend Call Working As Protalix BioTherapeutics Stock Rises 9.4% (PLX)
Comtex SmarTrend(R) - Fri Mar 07, 11:24AM CST
SmarTrend identified an Uptrend for Protalix BioTherapeutics (AMEXLX) on February 10th, 2014 at $4.67. In approximately 4 weeks, Protalix BioTherapeutics has returned 9.40% as of today's recent price of $5.10.

Godliness and Hard Work
by Adam Hartman - All Africa Global Media - Thu Feb 13, 6:11AM CST
OTJIMBINGWE'S Da-Palm Senior Secondary School's recipe for producing best Grade 12 results is simple - Godliness and hard work - according to the principal.

Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014
GlobeNewswire - Wed Feb 12, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor Ari Zimran at the 10th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2014 being held February 10-13 in San Diego, CA. Oral GCD is the Company's orally-delivered proprietary formulation of the plant cell-expressed enzyme, glucocerebrosidase (GCD), and contains the same active substance as taliglucerase alfa (ELELYSO(TM)), the Company's approved enzyme replacement therapy.

Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial Property
GlobeNewswire - Thu Feb 06, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that the Brazilian National Institute of Industrial Property (INPI) has approved the Company's previously-announced supply and technology transfer agreement with Fundacão Oswaldo Cruz (commonly referred to as Fiocruz), an arm of the Brazilian Ministry of Health for UPLYSO(TM) (alfataliglicerase). The Company announced the execution of the supply and technology transfer agreement on June 19, 2013, and receipt of the approval results in the final effectiveness of the agreement as of January 23, 2014. The Company has already completed the first shipment of the drug to Brazil under the agreement.

IHG Opens Crowne Plaza Hotel Near JFK International Airport
M2 - Fri Jan 31, 12:02PM CST
InterContinental Hotels Group has expanded its portfolio of New York hotels with the opening of the Crowne Plaza JFK Airport New York City hotel.

Protalix Announces Successful Manufacturing Facility Evaluation by Health Canada
GlobeNewswire - Thu Jan 23, 3:30PM CST
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that Health Canada has completed a successful on-site evaluation of the Company's manufacturing facility in Carmiel, Israel, as part of its ongoing review of the new drug submission (NDS) for taliglucerase alfa for the treatment of Gaucher disease. The purpose of the on-site evaluation was to verify the facility's compliance with certain Canadian food and drug regulations and, upon completion of the evaluation, Health Canada recommended approval from a facility perspective. A decision on final marketing approval of taliglucerase alfa in Canada is expected during 2014.

3 High-Risk, High-Reward Biotech Stocks for Long Term Investors
Maxx Chatsko, The Motley Fool - Motley Fool - Wed Jan 22, 4:02PM CST
Investors love being early adopters and supporters of innovative and disruptive companies, especially biotech companies, which can yield outsized gains. Unfortunately, it can be difficult to decipher which developmental companies truly have an edge,...

2 Biotech Stocks Under $10 to Watch
at The Street - Fri Jan 17, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.

Hot Stock: Protalix BioTherapeutics, Shares Gain 7.3% (PLX)
Comtex SmarTrend(R) - Mon Jan 13, 10:14AM CST
Protalix BioTherapeutics (AMEXLX) is one of today's best performing low-priced stocks, up 7.3% to $4.85 on 1.2x average daily volume. Thus far today, Protalix BioTherapeutics has traded 343,000 shares, vs. average volume of 284,000 shares per day. The stock has outperformed the Dow (7.3% to the Dow's -0.0%) and outperformed the S&P 500 (7.3% to the S&P's -0.0%) during today's trading.

Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook
GlobeNewswire - Mon Jan 13, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will discuss the Company's corporate objectives and key milestones in a presentation at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 12:00 PM, Pacific Time. Dr. Aviezer's presentation will include a discussion of the Company's 2014 strategic outlook and clinical highlights. A live webcast of the presentation will be available at www.protalix.com on the event calendar page, and will be archived for 90 days.

Traders Get Bullish on Shares of Protalix BioTherapeutics, Shares Up 8.4% (PLX)
Comtex SmarTrend(R) - Wed Jan 08, 11:42AM CST
Protalix BioTherapeutics (AMEXLX) is one of today's best performing low-priced stocks, up 8.4% to $4.41 on 1.0x average daily volume. Thus far today, Protalix BioTherapeutics has traded 306,000 shares, vs. average volume of 292,000 shares per day. The stock has outperformed the Dow (8.4% to the Dow's -0.4%) and outperformed the S&P 500 (8.4% to the S&P's -0.0%) during today's trading.

Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 07, 6:30AM CST
Protalix BioTherapeutics, Inc. (NYSE MKTLX) (TASELX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 12:00 PM, Pacific Time. The conference will be held at the Westin St. Francis Union Square Hotel in San Francisco on January 13-16, 2014. A live webcast of the presentation will be available at www.protalix.com on the event calendar page. A replay will be archived and available after the conclusion of the presentation for 90 days.

Idenix Pharmaceuticals (IDIX) Soars: Stock Adds 18.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 26, 7:11AM CST
Idenix Pharmaceuticals (IDIX) was a big mover last session, as the company saw its shares jump over 18% on the day.

Protalix BioTherapeutics Inc. Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 27, 5:16AM CST
Protalix BioTherapeutics Inc. Enters Oversold Territory

Protalix BioTherapeutics Down 7.3%, Shares Slide into the Red (PLX)
Comtex SmarTrend(R) - Mon Nov 25, 10:29AM CST
Protalix BioTherapeutics (AMEXLX) is one of today's worst performing low-priced stocks, down 7.3% to $3.96 on 1.0x average daily volume. Thus far today, Protalix BioTherapeutics has traded 226,000 shares, vs. average volume of 216,000 shares per day. The stock has underperformed the Dow (-7.3% to the Dow's 0.2%) and underperformed the S&P 500 (-7.3% to the S&P's 0.0%) during today's trading.

Will Omnivision (OVTI) Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 25, 8:00AM CST
Omnivision Technology is set to report second-quarter fiscal 2014 results on Nov 25.

The Simplest Biotech Growth Portfolio Ever
Maxx Chatsko, The Motley Fool - Motley Fool - Mon Nov 18, 5:06PM CST
The eye-popping booms of the biotech industry attract many investors, while the demoralizing busts scare plenty more away. It can be a daunting task to identify a biotech company with the potential to successfully commercialize a revolutionary...

Maxim Prices Senior Notes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 18, 12:20PM CST
Maxim Integrated Products, Inc. has recently announced the pricing of senior unsecured notes aggregating $500 million.

Is This Orphan Drugmaker in Trouble?
Leo Sun, The Motley Fool - Motley Fool - Mon Nov 11, 1:30PM CST
Protalix BioTherapeutics , an Israeli company focused on the treatment of Gaucher disease and other rare diseases, recently reported its third-quarter earnings. But its core business -- a joint venture with Pfizer to sell its Gaucher disease drug...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 162

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 35

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 10

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 72

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 117

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 73

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 231

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 194

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Generative AI Chipset Market Growth

Updated Category News Views 252

Generative AI Chipset Market Size Analysis The Generative AI Chipset Market is experiencing remarkable growth as the demand for high-performance AI hardware accelerates across various industries. Currently valued at approximately USD 37.29 billion in 2023, the market is anticipated to reach an impressive USD 454.50 billion by 2032, representing a staggering compound...

Continue Reading
CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer

Updated Category News Views 297

CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer CrateDB, the groundbreaking real-time database solution designed for analytics, search, and AI applications, has announced the exciting appointment of Robert Ekstrom as the new Chief Executive Officer. His leadership is viewed as a pivotal moment for the company, propelling its growth strategies and...

Continue Reading
Novartis AGM Highlights: Board Changes and Dividend Increase

Updated Category News Views 463

Key Outcomes from Novartis' Annual General Meeting Today, Novartis held its Annual General Meeting (AGM) where shareholders gathered to discuss and approve various resolutions proposed by the Board of Directors. It was an important day for the company, as a strong turnout highlighted investor engagement and confidence. Dividend Increase for 2024 This year marks a...

Continue Reading
Understanding Alliance Witan PLC's Net Asset Valuation Insights

Updated Category News Views 116

Understanding Alliance Witan PLC's Financial Standing Alliance Witan PLC stands out in the investment landscape, offering its shareholders a detailed look at their Net Asset Value (NAV). As of the latest reporting date, the financial metrics reveal significant information pertaining to the company's performance and shareholder value. Net Asset Value Calculation At the...

Continue Reading
Remembering Jimmy Carter: A Legacy of Service and Humanity

Updated Category News Views 375

Remembering Jimmy Carter: A Legacy of Service and Humanity Habitat for Humanity joins millions around the globe in reflecting on the remarkable life of former U.S. President Jimmy Carter. He is widely recognized not only as a political leader but also as a formidable advocate for affordable housing. A Champion for Affordable Housing Throughout his life, President Carter...

Continue Reading